Trial Profile
A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 May 2019 This trail has been completed in Denmark.
- 01 Dec 2009 Results published in Pediatric Allergy and Immunology.
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.